Parameters | No. of patients (n = 227) | Median survival (months) | χ2 | P * |
---|---|---|---|---|
Gender | 1.73 | 0.179 | ||
Male | 119 | 48 (21–78) | ||
Female | 108 | 43 (19–65) | ||
Age (years) | 1.22 | 0.270 | ||
≤ 60 | 132 | 38 (16–55) | ||
> 60 | 95 | 41 (20–62) | ||
Response to neoadjuvant chemotherapy | 19.40 | < 0.001 | ||
PR | 170 | 62 (22–81) | ||
SD | 35 | 35 (16–48) | ||
PD | 22 | 25 (13–41) | ||
Location of tumor | 0.76 | 0.859 | ||
Upper | 42 | 41 (22–49) | ||
Middle | 102 | 37 (20–51) | ||
Lower | 52 | 49 (16–72) | ||
Diffuse infiltration | 31 | 38 (16–57) | ||
Differentiation of tumor | 8.77 | 0.591 | ||
High | 80 | 35 (16–71) | ||
Middle | 46 | 39 (33–51) | ||
Poor | 49 | 33 (19–57) | ||
Signet ring cell | 52 | 31 (21–49) | ||
Surgical type | 9.45 | 0.009 | ||
Subtotal | 118 | 50 (21–79) | ||
Total | 68 | 31 (18–62) | ||
Combination of organs | 41 | 34 (19–56) | ||
Vascular invasion | 4.82 | 0.028 | ||
No | 161 | 44 (20–75) | ||
Yes | 66 | 32 (12–43) | ||
Borrman’s classification | 10.13 | 0.018 | ||
1 | 32 | 43 (14–68) | ||
2 | 56 | 63 (30–84) | ||
3 | 97 | 40 (18–64) | ||
4 | 41 | 28 (20–45) | ||
Lauren’s classification | 1.28 | 0.526 | ||
1 | 100 | 46 (20–69) | ||
2 | 82 | 40 (16–71) | ||
3 | 43 | 29 (16–51) | ||
ypT stage | 35.95 | < 0.001 | ||
ypT1 | 12 | 58 (19–81) | ||
ypT2 | 32 | 47 (16–65) | ||
ypT3 | 63 | 62 (29–91) | ||
ypT4a | 98 | 27 (16–47) | ||
ypT4b | 22 | 22 (14–38) | ||
Tumor volume (ypTV) | 25.74 | < 0.001 | ||
ypTV1 | 51 | 53 (27–78) | ||
ypTV2 | 49 | 47 (24–76) | ||
ypTV3 | 73 | 41 (22–64) | ||
ypTV4a | 23 | 31 (14–49) | ||
ypTV4b | 31 | 17 (10–47) | ||
Number of resected lymph nodes | 1.77 | 0.183 | ||
≤ 16 | 41 | 38 (18–54) | ||
> 16 | 186 | 41 (19–69) | ||
ypN stage | 18.27 | < 0.001 | ||
ypN0 | 66 | 48 (37–61) | ||
ypN1 | 50 | 40 (16–70) | ||
ypN2 | 39 | 35 (20–59) | ||
ypN3 | 72 | 28 (15–50) | ||
ypTNM stage | 2.40 | 0.210 | ||
I | 31 | 57 (41–82) | ||
II | 48 | 47 (36–70) | ||
III | 148 | 32 (15–49) | ||
ypTvNM stage | 21.23 | < 0.001 | ||
I | 37 | 67 (41–89) | ||
II | 57 | 44 (22–69) | ||
III | 133 | 32 (14–62) |